Fosgonimeton
Based on 1 Customer Validation
Fosgonimeton (ATH-1017) is a hepatocyte growth factor receptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models.
For research use only. We do not sell to patients.
- Purity: 98.24%
- CAS No.: 2093305-05-4
- Formula: C27H45N4O8P
- Molecular Weight:584.64
-
Storage:
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Biological Activity
Fosgonimeton (100 nM-1μM) can restore cell viability and increase mitochondrial membrane potential in neurotoxin-treated rat cortical neurons[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Fosgonimeton (0.125-1.25 mg/kg; Subcutaneous injection; 14 days) improves cognitive impairment in a LPS (HY-D1056) -induced neuroinflammation model of dementia mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Aβ peptides treated adult male Wistar rats (approximately 210 g)[2]
-
Dosage:0.125 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg and 2 mg/kg
-
Administration:Subcutaneous injection (s.c.); 14 days
-
Result:Significantly restored cognitive function at all doses tested.
The maximum average degree of recovery was 88% recovery in 0.125 mg/kg treated group.
-
Animal Model:LPS (HY-D1056) treated CD-1 mice aged four to five weeks old[3]
-
Dosage:0.125 mg/kg, 0.25 mg/kg, 0.5 mg/kg and 1.25 mg/kg
-
Administration:Subcutaneous injection (s.c.); 14 days
-
Result:Significantly ameliorated cognitive deficits at all doses tested, except for the lowest dose (0.125 mg/kg) tested.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 2093305-05-4
-
Appearance Solid
-
Molecular Weight 584.64
-
Formula C27H45N4O8P
-
Color White to off-white
-
SMILES
O=P(O)(O)OC(C=C1)=CC=C1C[C@H](NC(CCCCC)=O)C(N[C@@H]([C@@H](C)CC)C(NCCCCCC(N)=O)=O)=O
-
Synonyms
ATH-1017
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
DMSO : 125 mg/mL (213.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (272 KB)
-
SDS (786 KB)
- English - EN (786 KB)
- Français - FR (786 KB)
- Deutsch - DE (786 KB)
- Norwegian - NO (786 KB)
- Español - ES (786 KB)
- Swedish - SV (786 KB)
- Italian - IT (786 KB)
- Korean - KR (786 KB)
- Portuguese - PT (786 KB)
-
Handling Instructions (2659 KB)
References
[2]. Reda SM, et al. Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease. Neurotherapeutics. 2024 Jul;21(4):e00350. [Content Brief]
[3]. Johnston JL, et al. Fosgonimeton, a Novel Positive Modulator of the HGF/MET System, Promotes Neurotrophic and Procognitive Effects in Models of Dementia. Neurotherapeutics. 2023 Mar;20(2):431-451. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7105 mL | 8.5523 mL | 17.1045 mL | 42.7614 mL |
| 5 mM | 0.3421 mL | 1.7105 mL | 3.4209 mL | 8.5523 mL | |
| 10 mM | 0.1710 mL | 0.8552 mL | 1.7105 mL | 4.2761 mL | |
| 15 mM | 0.1140 mL | 0.5702 mL | 1.1403 mL | 2.8508 mL | |
| 20 mM | 0.0855 mL | 0.4276 mL | 0.8552 mL | 2.1381 mL | |
| 25 mM | 0.0684 mL | 0.3421 mL | 0.6842 mL | 1.7105 mL | |
| 30 mM | 0.0570 mL | 0.2851 mL | 0.5702 mL | 1.4254 mL | |
| 40 mM | 0.0428 mL | 0.2138 mL | 0.4276 mL | 1.0690 mL | |
| 50 mM | 0.0342 mL | 0.1710 mL | 0.3421 mL | 0.8552 mL | |
| 60 mM | 0.0285 mL | 0.1425 mL | 0.2851 mL | 0.7127 mL | |
| 80 mM | 0.0214 mL | 0.1069 mL | 0.2138 mL | 0.5345 mL | |
| 100 mM | 0.0171 mL | 0.0855 mL | 0.1710 mL | 0.4276 mL |